DE60223812T2 - Methode zur virusvermehrung - Google Patents

Methode zur virusvermehrung Download PDF

Info

Publication number
DE60223812T2
DE60223812T2 DE60223812T DE60223812T DE60223812T2 DE 60223812 T2 DE60223812 T2 DE 60223812T2 DE 60223812 T DE60223812 T DE 60223812T DE 60223812 T DE60223812 T DE 60223812T DE 60223812 T2 DE60223812 T2 DE 60223812T2
Authority
DE
Germany
Prior art keywords
virus
temperature
chordopox
mva
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60223812T
Other languages
German (de)
English (en)
Other versions
DE60223812D1 (de
Inventor
Paul Berwick HOWLEY
Karl Heller
Ingmar Räthe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bavarian Nordic AS
Original Assignee
Bavarian Nordic AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8160630&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60223812(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bavarian Nordic AS filed Critical Bavarian Nordic AS
Application granted granted Critical
Publication of DE60223812D1 publication Critical patent/DE60223812D1/de
Publication of DE60223812T2 publication Critical patent/DE60223812T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/065—Poxviridae, e.g. avipoxvirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/065—Poxviridae, e.g. avipoxvirus
    • C07K14/07—Vaccinia virus; Variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24051—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
DE60223812T 2001-07-18 2002-07-02 Methode zur virusvermehrung Expired - Lifetime DE60223812T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK200101122 2001-07-18
DKPA200101122 2001-07-18
PCT/EP2002/007280 WO2003008533A2 (en) 2001-07-18 2002-07-02 Method for virus propagation

Publications (2)

Publication Number Publication Date
DE60223812D1 DE60223812D1 (de) 2008-01-10
DE60223812T2 true DE60223812T2 (de) 2008-11-13

Family

ID=8160630

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60223812T Expired - Lifetime DE60223812T2 (de) 2001-07-18 2002-07-02 Methode zur virusvermehrung

Country Status (19)

Country Link
US (1) US6924137B2 (enExample)
EP (1) EP1412486B1 (enExample)
JP (2) JP4700907B2 (enExample)
KR (1) KR100908377B1 (enExample)
CN (1) CN100513560C (enExample)
AU (1) AU2002314201B2 (enExample)
BR (2) BRPI0211276B1 (enExample)
CA (1) CA2450206C (enExample)
DE (1) DE60223812T2 (enExample)
DK (1) DK1412486T3 (enExample)
EA (1) EA006628B1 (enExample)
HU (1) HUP0400393A3 (enExample)
IL (2) IL158927A0 (enExample)
MX (1) MXPA04000326A (enExample)
NO (1) NO339056B1 (enExample)
NZ (1) NZ529914A (enExample)
PL (1) PL205926B1 (enExample)
UA (1) UA82466C2 (enExample)
WO (1) WO2003008533A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1335987T4 (en) * 2000-11-23 2016-09-19 Bavarian Nordic As Modified variant of vaccinia virus Ankara
WO2004022729A1 (en) * 2002-09-05 2004-03-18 Bavarian Nordic A/S Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
TWI638829B (zh) 2012-07-10 2018-10-21 法商傳斯堅公司 分枝桿菌抗原疫苗
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
US10765731B2 (en) 2014-01-09 2020-09-08 Transgene Sa Fusion of heterooligomeric mycobacterial antigens
ES3011733T3 (en) 2015-02-13 2025-04-08 Transgene Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
US10913063B2 (en) * 2016-07-12 2021-02-09 EMULATE, Inc. Removing bubbles in a microfluidic device
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
SG11201912429RA (en) 2017-06-21 2020-01-30 Transgene Sa Personalized vaccine
EP3842065A1 (en) 2019-12-23 2021-06-30 Transgene Process for designing a recombinant poxvirus for a therapeutic vaccine
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
AU2024241503A1 (en) 2023-03-17 2025-08-14 Albert-Ludwigs-Universität Freiburg Hbv antigen formulation for treating hepatitis b
WO2025172435A1 (en) 2024-02-13 2025-08-21 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Hbv antigen formulation for treating hepatitis b
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2384845A1 (fr) * 1976-08-05 1978-10-20 Anvar Vaccin contre la myxomatose et nouvelle souche virale utilisee
JPS60202827A (ja) * 1984-03-28 1985-10-14 Chibaken 弱毒痘そうワクチン株
CA1341245C (en) * 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5616487A (en) * 1994-09-15 1997-04-01 Aastrom Biosciences, Inc. Stabilized retrovirus compositions
WO1997012032A1 (en) * 1995-09-27 1997-04-03 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Production of infectious respiratory syncytial virus from cloned nucleotide sequences
EP0912724B1 (en) * 1996-07-15 2009-12-09 The Government of The United States of America, as represented by The Department of Health and Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
DK1335987T4 (en) * 2000-11-23 2016-09-19 Bavarian Nordic As Modified variant of vaccinia virus Ankara

Also Published As

Publication number Publication date
PL366897A1 (en) 2005-02-07
US6924137B2 (en) 2005-08-02
EP1412486B1 (en) 2007-11-28
BRPI0211276B1 (pt) 2018-12-04
JP2011078424A (ja) 2011-04-21
EA006628B1 (ru) 2006-02-24
KR100908377B1 (ko) 2009-07-20
EP1412486A2 (en) 2004-04-28
EA200400195A1 (ru) 2004-06-24
US20040234950A1 (en) 2004-11-25
JP4700907B2 (ja) 2011-06-15
WO2003008533A2 (en) 2003-01-30
CN1533433A (zh) 2004-09-29
BR0211276A (pt) 2004-08-03
HK1066245A1 (zh) 2005-03-18
KR20040018474A (ko) 2004-03-03
HUP0400393A3 (en) 2004-10-28
UA82466C2 (uk) 2008-04-25
AU2002314201B2 (en) 2006-09-21
CN100513560C (zh) 2009-07-15
NZ529914A (en) 2005-03-24
MXPA04000326A (es) 2005-03-07
NO339056B1 (no) 2016-11-07
NO20040158L (no) 2004-01-13
DK1412486T3 (da) 2008-03-10
JP5154632B2 (ja) 2013-02-27
WO2003008533A3 (en) 2004-01-08
PL205926B1 (pl) 2010-06-30
JP2004535203A (ja) 2004-11-25
CA2450206C (en) 2012-08-21
IL158927A (en) 2009-09-01
CA2450206A1 (en) 2003-01-30
DE60223812D1 (de) 2008-01-10
IL158927A0 (en) 2004-05-12
HUP0400393A2 (hu) 2004-07-28

Similar Documents

Publication Publication Date Title
DE60223812T2 (de) Methode zur virusvermehrung
US8329466B2 (en) Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
DE60314823T2 (de) Modifizierte variante des vaccinia ankara virus als impfstoff für neugeborene
DE60205388T2 (de) Poxvirus-enthaltende zusammensetzungen und verfahren zu ihrer herstellung
DE60205631T2 (de) Methode zur gewinnung und reinigung von poxviren aus infizierten zellen
AU2002314201A1 (en) Method for virus propagation
JP2004535203A5 (enExample)
DE10144664B4 (de) Vacciniavirus MVA-E3L-Knock-Out-Mutanten und Verwendung hiervon
DE69535092T2 (de) HERPESVIREN, UM gD IN VITRO ZU EXPRIMIEREN
HK1066245B (en) Method for virus propagation

Legal Events

Date Code Title Description
8363 Opposition against the patent